[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573221":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":26,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Rifaximin+SOC","EXPERIMENTAL","Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7 SOC (Standard of care) means both group will recieve similar post of care which is standard protocol at ILBS.",[13,14],"Drug: Rifaximin 550 MG","Other: SOC",{"label":16,"type":17,"description":18,"interventionNames":19},"Non Rifaximin + SOC","ACTIVE_COMPARATOR","SOC (Standard of care) means both group will recieve similar post of care which is standard protocol at ILBS.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rifaximin 550 MG","Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"SOC","SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.",[16,9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Tapan Kumar Pradhan, MS","CONTACT","9970189001","tapan.ravi94@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Nilesh Sadashiv Patil, MCh","01146300000","dr.nils.p@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Insitute of Liver and Biliary Sciences","RECRUITING","New Delhi","National Capital Territory of Delhi","110070","India","IN",{"type":51,"coordinates":52},"Point",[53,54],77.2148,28.62137,{"lat":54,"lon":53},[57],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100573221","effect-of-perioperative-oral-rifaximin-on-early-graft-dysfunction-in-adult-living-donor-liver-transplant-100573221",false,"NCT06743464","Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant","Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant: An Open Label Randomized Control Trial","Inclusion Criteria:\n\n* All recipients (adults) undergoing living donor liver transplant in ILBS.\n\nExclusion Criteria:\n\n* Negative consent\n\n  * Hypersensitivity to Rifaximin\n  * Patients undergoing retransplant\n  * ALF, ACLF\n  * Pediatrics patients\n  * Patients on rifaximin","ALL","18 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"NA","Liver transplantation has been a lifesaving treatment for individuals with end stage liver disease and acute liver failure. However, initial poor function of a liver allograft after liver transplantation, termed early graft dysfunction (EGD), has been associated with increased allograft loss or mortality after transplantation. EGD in LDLT is multifactorial. Factors affecting EGD are GRWR, ischemia reperfusion injury, recipient metabolic demand, graft quality, graft inflow and outflow. Studies shows that the incidence of EGD is 15-38%. It is associated with increased allograft loss \\& mortality. Rifaximin is an antibiotic that reduces EGD by 50% as shown by 2 studies but this study was done in DDLT setting and rifaximin was given in the pretransplant group.\n\nIn this investigators will study the effect of perioperative oral rifaximin on early graft dysfunction in adult living donor liver transplant.",[77],"Chronic Liver Disease","2025-03-04",{"date":80,"type":81},"2025-03-05","ACTUAL",{"date":83,"type":81},"2024-12-01",{"date":85,"type":71},"2025-12-31",{"name":5,"class":6},1]